Winette van der Graaf, President of the EORTC, Professor of Medical Oncology at The Netherlands Cancer Institute, and Founding Member of Common Sense Oncology, shared a post on LinkedIn by European Organisation for Research and Treatment of Cancer, adding:
“This EORTC – European Organisation for Research and Treatment of Cancer Global Strategy Meeting was meant to learn from the perspectives from our colleagues from all over the world on their ability to run clinical trials in their organisations and healthcare systems to improve outcomes for patients and also (their) healthcare systems. Clearly, the needs and challenges are different, but there was a lot of commonality in the wish and ambition to bring this independent clinical research to a higher level and work on this as global partners together.
Topics, such as optimisation of diagnostics, local and systemic treatments (dose, duration, schedule, timing of different treatment modalities, optimisation of patients’ input in the whole design and execution of clinical trials) were highlighted and we concluded that we need to move forward now.
I am incredibly grateful to all the people at Headquarters of EORTC, and particularly to
Denis Lacombe, who have put a lot of effort into bringing us all together, to my co-chair Martin Stockler, to Elizabeth Eisenhauer for her inspiring keynote lecture and last but not least to all our colleagues who have taken the time and effort to travel all the way to Brussels.
This meeting was only a start and we will work on the ‘low hanging fruit’ soon and the more difficult nuts to crack in a stronger collaborative spirit than ever before.”
Quoting European Organisation for Research and Treatment of Cancer’s post:
“We’ve just wrapped up the EORTC 2026 Global Strategy meeting at EORTC HQ!
Two inspiring days bringing together global leaders committed to strengthening academic independent patient‑centred clinical cancer research.
We explored future models for global cooperation, identified common priorities, and aligned on how to ensure academic clinical trials continue delivering robust evidence for patients worldwide.
A powerful reminder of what makes EORTC unique: our ability to bring diverse voices together, to reflect collectively, and to reshape our scientific agenda with openness and intention.
Stay tuned for more info!”
Other articles featuring Winette van der Graaf on OncoDaily.